Matthew C Abramowitz

List of Publications by Year
in descending order

50 papers	1,144 citations	567281 15 h-index	395702 33 g-index
50 all docs	50 docs citations	50 times ranked	2180 citing authors

#	Article	IF	Citations
1	Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. Journal of Clinical Oncology, 2016, 34, 3648-3654.	1.6	296
2	The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer, 2008, 112, 55-60.	4.1	156
3	Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies. Oncotarget, 2016, 7, 53362-53376.	1.8	90
4	Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncology, 2018, 4, e175230.	7.1	65
5	Active surveillance vs. treatment for low-risk prostate cancer: A cost comparison. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 576-580.	1.6	54
6	Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomyâ€"A Multi-Institutional Observational Study. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1046-1053.	0.8	47
7	Segmentation of prostate and prostate zones using deep learning. Strahlentherapie Und Onkologie, 2020, 196, 932-942.	2.0	36
8	Ethnic heterogeneity and prostate cancer mortality in Hispanic/Latino men: a population-based study. Oncotarget, 2017, 8, 69709-69721.	1.8	30
9	Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. European Urology, 2018, 74, 99-106.	1.9	28
10	Head and neck second primary cancer rates in the human papillomavirus era: A populationâ€based analysis. Head and Neck, 2016, 38, E873-83.	2.0	26
11	Magnetic resonance imaging (MRI)-based radiomics for prostate cancer radiotherapy. Translational Andrology and Urology, 2018, 7, 445-458.	1.4	26
12	The role of radiomics in prostate cancer radiotherapy. Strahlentherapie Und Onkologie, 2020, 196, 900-912.	2.0	24
13	Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Radiotherapy and Oncology, 2016, 121, 294-298.	0.6	22
14	Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 107, 305-315.	0.8	20
15	Ethnicity and Clinical Outcomes in Head and Neck Cancer: an Analysis of the SEER Database. Journal of Racial and Ethnic Health Disparities, 2014, 1, 267-274.	3.2	17
16	Postprostatectomy Radiation Therapy for Prostate Cancer. Seminars in Radiation Oncology, 2008, 18, 15-22.	2.2	16
17	An Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System forÂDefining External Beam Radiation Therapy Boost Volumes. International Journal of Radiation Oncology Biology Physics, 2018, 102, 821-829.	0.8	16
18	Repeatability of CBCT radiomic features and their correlation with CT radiomic features for prostate cancer. Medical Physics, 2021, 48, 2386-2399.	3.0	13

#	Article	IF	Citations
19	Dermal Lymphatic Invasion and Inflammatory Breast Cancer Are Independent Predictors of Outcome After Postmastectomy Radiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 30-33.	1.3	12
20	Automatic Detection and Quantitative DCE-MRI Scoring of Prostate Cancer Aggressiveness. Frontiers in Oncology, 2017, 7, 259.	2.8	12
21	Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy. European Urology Oncology, 2022, 5, 304-313.	5.4	12
22	Margin verification for hypofractionated prostate radiotherapy using a novel dose accumulation workflow and iterative CBCT. Physica Medica, 2020, 77, 154-159.	0.7	11
23	Feasibility and Initial Dosimetric Findings forÂaÂRandomized Trial Using Dose-Painted Multiparametric Magnetic Resonance Imagingâ€“Defined Targets in Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 827-834.	0.8	10
24	Weighing the Addition of Androgen Suppression Therapy to Radiotherapy Dose Escalation for Intermediate-Risk Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 1715-1717.	1.6	9
25	Towards a universal MRI atlas of the prostate and prostate zones. Strahlentherapie Und Onkologie, 2019, 195, 121-130.	2.0	9
26	Assessment of Rigid Registration Quality Measures in Ultrasound-Guided Radiotherapy. IEEE Transactions on Medical Imaging, 2018, 37, 428-437.	8.9	8
27	Automatic Detection of Prostate Tumor Habitats using Diffusion MRI. Scientific Reports, 2018, 8, 16801.	3.3	8
28	Assessment of specific versus combined purpose knowledge based models in prostate radiotherapy. Journal of Applied Clinical Medical Physics, 2018, 19, 209-216.	1.9	8
29	Assessment of CT to CBCT contour mapping for radiomic feature analysis in prostate cancer. Scientific Reports, 2021, 11, 22737.	3.3	7
30	Clinicogenomic characterization of prostate cancer liver metastases. Prostate Cancer and Prostatic Diseases, 2022, 25, 366-369.	3.9	7
31	Concurrent Radiotherapy with Carboplatin and Cetuximab for the Treatment of Medically Compromised Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2014, 4, 165.	2.8	5
32	Neoadjuvant Radiotherapy Improves Survival in Patients With T2b/T3 Bladder Cancer: A Population-Based Analysis. Clinical Genitourinary Cancer, 2015, 13, 378-384.e1.	1.9	5
33	Acute Epithelial Toxicity Is Prognostic for Improved Prostate Cancer Response to Radiation Therapy: A Retrospective, Multicenter, Cohort Study. International Journal of Radiation Oncology Biology Physics, 2018, 101, 957-963.	0.8	5
34	Contemporary role of postoperative radiotherapy for prostate cancer. Translational Andrology and Urology, 2018, 7, 399-413.	1.4	5
35	Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy. Journal of Urology, 2021, 205, 1344-1351.	0.4	5
36	Quantification of the margin required for treating intraprostatic lesions. Journal of Applied Clinical Medical Physics, 2016, 17, 304-312.	1.9	4

#	Article	IF	Citations
37	Dynamic contrast-enhanced MRI for automatic detection of foci ï»¿of residual or recurrent disease after prostatectomy. Strahlentherapie Und Onkologie, 2017, 193, 13-21.	2.0	4
38	Levels of Evidence for Radiation Therapy Recommendations in the National Comprehensive Cancer Network (NCCN) Clinical Guidelines. Advances in Radiation Oncology, 2022, 7, 100832.	1.2	4
39	Moderate hypofractionated radiotherapy â€" not yet a standard of care. Nature Reviews Clinical Oncology, 2016, 13, 655-656.	27.6	3
40	Opioid use patterns in patients with head and neck cancer receiving radiation therapy: Singleâ€institution retrospective analysis characterizing patients who did not require opioid therapy. Head and Neck, 2021, 43, 2973-2984.	2.0	2
41	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genetics, 2021, 258-259, 61-68.	0.4	2
42	A Single Axial Slice of the Sternocleidomastoids and Paravertebral Muscles Associated with Worse Local Progression-Free Survival and Severe Toxicity in Sarcopenic Head and Neck Cancer Patients Undergoing Radiotherapy. Cureus, 2022, 14, e22463.	0.5	2
43	Bladder Carcinoma. Medical Radiology, 2014, , 377-386.	0.1	1
44	Local Treatment in Metastatic Prostate Cancer: A Cultural Shift Confronts Power and Selection. European Urology, 2019, 75, 419-422.	1.9	1
45	A meta-analysis of health-related quality of life after primary treatment for prostate cancer as measured by the Expanded Prostate Cancer Index Composite.. Journal of Clinical Oncology, 2015, 33, 39-39.	1.6	1
46	Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy.. Journal of Clinical Oncology, 2017, 35, 9-9.	1.6	0
47	Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy.. Journal of Clinical Oncology, 2017, 2017, 9-9.	1.6	0
48	Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis.. Journal of Clinical Oncology, 2018, 36, 24-24.	1.6	0
49	Hypofractionated radiotherapy for prostate cancer: has the time come?. Oncology, 2012, 26, 519, 522.	0.5	0
50	Diagnosis and treatment of metastatic prostate cancer. , 2022, , 23-47.		0